



CENTRAL PHARMACEUTICAL CPC1.JSC

FINANCIAL STATEMENTS

Quarter 2/2025

CONTENTS

	<i>Page</i>
General information	3 - 4
Balance sheet	5 - 6
Income statement	7 - 8
Cash flow statement	9 - 10
Notes to the financial statements	11 - 36



GENERAL INFORMATION

THE COMPANY

Central Pharmaceutical CPC1.JSC ("the Company"), formerly known as Grade I Pharmaceutical Company, a State-owned enterprise under Vietnam Pharmaceutical Enterprises Union, and is now a subsidiary of Vietnam Pharmaceutical Corporation. On 29 June 2010, the Company has been officially transformed into Central Pharmaceutical One Member Limited Liability Company 1 in accordance with Decision No. 045/QĐ-TCTD of the Chairman of the Board of Directors of Vietnam Pharmaceutical Corporation. Pursuant to Decision No. 2290/QĐ-BYT dated 12 June 2015 of the Minister of Health approving the equitization plan, the Company was transformed to a joint stock company under the name Central Pharmaceutical CPC1.JSC and operates under the Business Registration Certificate No. 0100108536 issued on 4 January 2016.

The Company was approved to become a public company under Official Dispatch No. 3339/UBCK-GSĐC dated 29 May 2017 of the State Securities Commission. The Company's shares have been officially listed on the UPCoM since from 12 June 2018 under the stock code DP1.

The Company operates under the Business Registration Certificate No. 0100108536 issued by Hanoi Department of Planning and Investment on 4 January 2016. The Company also received subsequent amended Business Registration Certificates with the latest being the 16th amendmend granted on 6 May 2022.

The principal activities during the period of the Company are wholesale and retail of medicines, medical equipment, cosmetics and hygiene products.

The Company's head office is located at No. 87 Nguyen Van Troi Street, Phuong Liet Ward, Hanoi, Vietnam.

BOARD OF DIRECTORS

Members of the Board of Directors during the period and at the date of this report are:

Ms. Han Thi Khanh Vinh	Chairwoman
Mr. Nguyen Doan Liem	Member
Ms. Tran Thi Kim Khanh	Independent Member
Mr. Nguyen Huy Thanh	Member
Ms. Bui Thi Thanh Hai	Member

SUPERVISORY BOARD

Pursuant to the Resolution of the Annual General Meeting of Shareholders dated 11 April 2024, the Company's General Meeting of Shareholders approved the change of its organizational model, and to discontinue the use of the Board of Supervision, to dismiss existing members of the Board of Supervision and to establish Audit Committee under the Board of Directors. The members of the Supervisory Board during the period and up to the date of the change is as follows:

Ms. Luong Thi Kim Thanh	Head of Board	Resigned on 11 April 2024
Ms. Bui Thi Thanh Hai	Member	Resigned on 11 April 2024
Ms. Ha Lan Anh	Member	Resigned on 11 April 2024

AUDIT COMMITTEE

The members of the Audit Committee during the period and at the date of this report are as follows:

Ms. Tran Thi Kim Khanh	Chairwoman	Appointed on 12 June 2024
Mr. Nguyen Doan Liem	Member	Appointed on 12 June 2024

BOARD OF MANAGEMENT

The members of the Board of Management during the period and at the date of this report are as follows:

Mr. Ta Van Dung	Acting General Director
Ms. Nguyen Thi Hoa	Deputy General Director
Ms. Bui Thi Thanh Hai	Deputy General Director
Mr. Nguyen Huy Thanh	Deputy General Director

LEGAL REPRESENTATIVE

The legal representative of the Company during the period and at the date of this report is Ms. Han Thi Khanh Vinh - Chairwoman of the Board of Directors. Mr. Ta Van Dung - Acting General Director is authorized by Ms. Han Thi Khanh Vinh to sign the accompanying financial statements for the period ended 30 June 2025.

RESPONSIBILITY OF THE COMPANY'S BOARD OF MANAGEMENT IN RESPECT OF THE FINANCIAL STATEMENTS

The Board of Management is responsible for ensuring that the financial statements give a true and fair view of the financial position, results of operations and cash flows of the Company during the period. In preparing these financial statements, the Board of Directors has carried out:

- ▶ select suitable accounting policies and then apply them consistently;
- ▶ make judgements and accounting estimates that are reasonable and prudent ;
- ▶ state clearly whether the accounting standards applied to the Company have been complied or not and all material deviations from these standards have been presented and explained in the financial statements; and
- ▶ prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Company will continue in business.


The Board of Management is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the accounting records comply with the applied accounting system. The Board of Management is also responsible for safeguarding the assets of the Company and taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Board of Management confirms that it has complied with the above requirements in preparing the accompanying financial statements.

DECLARATION OF THE BOARD OF MANAGEMENT

The Board of Management does hereby state that, in its opinion, the accompanying financial statements give a true and fair view of the interim financial position of the Company as at 30 June 2025 and of the interim results of its operations and its cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the interim financial statements.

On behalf of the Board of Management:



Ta Van Dung
Acting General Director
Hanoi, 18 July 2025

BALANCE SHEET

As at 30 June 2025

Unit: VND

ITEM	Code	Notes	30 Jun 2025	01 Jan 2025
A. SHORT-TERM ASSETS	100		1,362,055,446,826	1,243,266,255,585
I. Cash and cash equivalents	110	V.1	57,961,321,212	9,507,536,737
1. Cash	111		57,961,321,212	9,507,536,737
II. Short-term financial investments	120	V.2		
III. Current accounts receivables	130		584,243,820,179	496,951,385,423
1. Short-term trade receivables	131	V.3	560,238,736,613	486,370,464,967
2. Short-term advances to suppliers	132		25,847,554,391	11,374,582,149
3. Short-term internal receivables	133		-	-
6. Other short-term receivables	136	V.4	1,055,888,073	2,376,495,796
7. Provision for doubtful short-term receivables (*)	137	V.5	(2,898,358,898)	(3,170,157,489)
IV. Inventories	140	V.6	702,230,644,279	715,839,688,988
1. Inventories	141		725,309,708,366	739,845,564,562
2. Provision for obsolete inventories(*)	149		(23,079,064,087)	(24,005,875,574)
V. Other current assets	150		17,619,661,156	20,967,644,437
1. Short-term prepaid expenses	151	V.10	1,066,244,373	1,840,213,756
2. Value-added tax deductible	152	V.13	15,892,699,533	18,898,395,710
3. Tax and other receivables from the State	153	V.13	660,717,250	229,034,971
B. LONG-TERM ASSETS	200		152,472,171,057	149,931,233,466
I. Long-term receivables	210		709,000,000	-
6. Other long-term receivables	216		709,000,000	-
II. Fixed assets	220		84,773,412,705	88,386,399,387
1. Tangible fixed assets	221	V.8	56,908,179,905	60,521,166,587
- Cost	222		214,315,145,753	214,315,145,753
- Accumulated depreciation (*)	223		(157,406,965,848)	(153,793,979,166)
3. Intangible fixed assets	227	V.9	27,865,232,800	27,865,232,800
- Cost	228		30,571,666,000	30,571,666,000
- Accumulated amortisation (*)	229		(2,706,433,200)	(2,706,433,200)
III. Investment real estate	230	V.9		
IV. Long-term assets in progress	240	V.7	4,675,385,590	362,866,667
2. Cost of construction in progress	242		4,675,385,590	362,866,667
V. Long-term financial investments	250		31,660,589,692	31,632,167,739
3. Investment in other entities	253		32,511,198,461	32,511,198,461
4. Provision for diminution in value of long-term investments (*)	254		(850,608,769)	(879,030,722)
VI. Other long-term assets	260		30,653,783,070	29,549,799,673
1. Long-term prepaid expenses	261	V.10	24,653,170,252	24,933,986,855
2. Deferred tax assets	262		6,000,612,818	4,615,812,818
TOTAL ASSETS (270 = 100 + 200)	270		1,514,527,617,883	1,393,197,489,051

BALANCE SHEET

As at 30 June 2025

Unit: VND

ITEM	Code	Notes	30 Jun 2025	01 Jan 2025
C. LIABILITIES	300		984,317,768,855	881,667,353,990
I. Short-term liabilities	310		982,255,910,063	881,667,353,990
1. Short-term trade payables	311	V.12	447,302,432,845	448,902,657,067
2. Short-term advances from customers	312		6,565,603,641	5,027,396,968
3. Tax and other payables to the State	313	V.13	49,621,588,043	47,529,365,909
4. Payables to employees	314		9,902,639,905	11,025,618,927
5. Short-term accrued expenses	315	V.14	8,183,303,085	5,446,809,923
6. Short-term internal payables	316		-	-
8. Short-term unearned revenues	318	V.16	1,190,560,000	1,539,221,331
9. Other short-term payables	319	V.15	26,825,581,952	18,872,364,887
10. Short-term loans	320	V.11	415,818,187,252	336,243,879,456
12. Bonus and welfare fund	322		16,846,013,340	7,080,039,522
II. Long-term liabilities	330		2,061,858,792	
B. OWNERS' EQUITY	400		530,209,849,028	511,530,135,061
I. Owners' equity	410	V.17	530,209,849,028	511,530,135,061
1. Owner's contributed equity	411		209,790,000,000	209,790,000,000
- Common shares with voting rights	411a		209,790,000,000	209,790,000,000
8. Investment and development fund	418		2,444,991,780	2,444,991,780
11. Undistributed earnings	421		317,974,857,248	299,295,143,281
- Undistributed earnings by the end of previous period	421a		264,354,369,463	204,319,740,049
- Undistributed earnings of current period	421b		53,620,487,785	94,975,403,232
II. Other resources and funds	430			
TOTAL RESOURCES (440 = 300 + 400)	440		1,514,527,617,883	1,393,197,489,051

Preparer
Truong Thi Hue

Financial Director
Tran Anh Tuan

Acting General Director
Ta Van Dung



Hanoi, 18 July 2025

INCOME STATEMENT

Quarter II 2025

Unit: VND

ITEMS	CODE	NOTES	Quarter II		Accumulated from beginning of year to end of this quarter	
			Current year	Previous year	Current year	Previous year
1. Revenue from goods sold and services rendered	01	VI.1	547,564,390,955	512,782,404,710	1,032,688,200,351	1,019,095,566,294
2. Deductions	02	VI.1				
3. Net revenue from goods sold and services rendered (10=01 - 02)	10		547,564,390,955	512,782,404,710	1,032,688,200,351	1,019,095,566,294
4. Cost of goods sold and services rendered	11	VI.2	469,441,773,151	431,481,665,858	873,792,522,328	846,324,498,595
5. Gross profit from goods sold and services rendered (20=10 - 11)	20		78,122,617,804	81,300,738,852	158,895,678,023	172,771,067,699
6. Finance income	21	VI.3	4,924,268,661	3,412,887,874	11,555,081,141	6,389,632,725
7. Finance expenses	22	VI.4	13,049,420,110	6,371,434,055	27,359,918,821	18,287,265,295
- In which: Interest expenses	23		4,372,840,315	2,762,710,064	8,401,478,788	6,134,671,848
8. Selling expenses	25	VI.7	31,418,614,336	33,769,569,134	60,237,638,162	63,817,640,010
9. General and administrative expenses	26	VI.7	13,495,135,250	16,679,689,610	18,779,233,889	24,388,025,440
10. Operating profit {30 = 20 + (21 - 22) - (25 + 26)}	30		25,083,716,769	27,892,933,927	64,073,968,292	72,667,769,679
11. Other income	31	VI.5	3,283,232,338		3,283,232,338	95,956,435
12. Other expenses	32	VI.6	284,399,653	25,267,435	309,241,806	40,192,435
13. Other profit (40 = 31 - 32)	40		2,998,832,685	(25,267,435)	2,973,990,532	55,764,000

INCOME STATEMENT

Quarter II 2025

Unit: VND

ITEMS	CODE	NOTES	Quarter II		Accumulated from beginning of year to end of this quarter	
			Current year	Previous year	Current year	Previous year
14. Accounting profit before tax (50 = 30 + 40)	50		28,082,549,454	27,867,666,492	67,047,958,824	72,723,533,679
15. Current corporate income tax expenses	51	VI.9	7,004,740,734	6,852,206,396	14,812,271,039	15,839,973,576
16. Deferred corporate income tax expense	52	VI.9	(1,384,800,000)	(1,293,055,318)	(1,384,800,000)	(1,293,055,318)
17. Net profit after tax (60 = 50 - 51 - 52)	60		22,462,608,720	22,308,515,414	53,620,487,785	58,176,615,421
18. Basic earnings per share (*)	70		1,071	1,063	2,556	2,539
19. Diluted earnings per share (*)	71		1,071	1,063	2,556	2,539

Hanoi, 18 July 2025

Preparer
Truong Thi Hue

Financial Director
Tran Anh Tuan



Acting General Director
Ta Van Dung

CASH FLOW STATEMENT

(By indirect method)

Quarter II 2025

Unit: VND

Items	Code	Notes	Accumulated from beginning of year to end of this quarter	
			Current year	Previous year
I. Cash flows from operating activities				
1. Accounting profit before tax	01		67,047,958,824	72,723,533,679
- Depreciation of fixed assets and investment real estate	02		3,612,986,682	3,898,897,657
- Provisions	03		(1,227,032,031)	7,620,732,435
- Foreign exchange losses, profits arisen from revaluation of monetary accounts denominated in foreign currency	04		3,966,135,357	61,581,246
- Profits, losses from investing activities	05		(259,192,470)	(209,292,709)
- Interest expenses	06		4,372,840,315	6,134,671,848
3. Operating profit before changes in working capital	08		77,513,696,677	90,230,124,156
- Increase, decrease in receivables	09		(85,155,622,267)	51,384,083,602
- Increase, decrease in inventories	10		14,535,856,196	(30,088,060,150)
- Increase, decrease in payables (excluding interests, CIT)	11		(7,142,352,745)	(7,742,934,251)
- Increase, decrease in prepaid expenses	12		1,054,785,986	328,558,599
- Interest paid	14		(4,123,637,022)	(6,216,545,089)
- Corporate income tax paid	15		(13,000,000,000)	(22,934,044,386)
- Other cash outflows for operating activities	17		9,765,973,818	(8,796,884,583)
Net cash flows from operating activities	20		(6,551,299,357)	66,164,297,898
II. Cash flows from investing activities				
1. Purchase and construction of fixed assets and other long-term assets	21		4,312,518,923	
2. Proceeds from disposals of fixed assets and other long-term assets	22		-	
3. Cash spent on lending and purchasing debt instruments of other entities	23		-	
4. Proceeds from loans and resale of debt instruments of other entities	24		-	
7. Interest, dividends and profits received	27		259,192,470	209,292,709

CASH FLOW STATEMENT

(By indirect method)

Quarter II 2025

Unit: VND

Items	Code	Notes	Accumulated from beginning of year to end of this quarter	
			Current year	Previous year
<i>Net cash flows from investing activities</i>	30		4,571,711,393	209,292,709
III. Cash flows from financing activities				
3. Drawdown of borrowings	33		577,953,505,095	355,001,391,564
4. Repayment of borrowings	34		(498,379,197,299)	(432,444,230,139)
6. Dividends paid	36		(25,174,800,000)	(5,700,000)
<i>Net cash flows from financing activities</i>	40		54,399,507,796	(77,448,538,575)
Net cash flow for the period (50 = 20+30+40)	50		52,419,919,832	(11,074,947,968)
Cash and cash equivalents at beginning of period	60		9,507,536,737	27,898,593,898
<i>Impact of exchange rate fluctuation</i>	61		(3,966,135,357)	(7,177,601)
Cash and cash equivalents at end of period (70 = 50+60+61)	70		57,961,321,212	16,816,468,329

[Signature]

Preparer
Truong Thi Hue

[Signature]
Financial Director
Tran Anh Tuan



[Signature]
Acting General Director
Ta Van Dung

Hanoi, 18 July 2025

NOTES TO THE FINANCIAL STATEMENTS

Quarter II 2025

1. COMPANY INFORMATION

Central Pharmaceutical CPC1.JSC ("the Company"), formerly known as Grade I Pharmaceutical Company, a State-owned enterprise under Vietnam Pharmaceutical Enterprises Union, and is now a subsidiary of Vietnam Pharmaceutical Corporation. On 29 June 2010, the Company has been officially transformed into Central Pharmaceutical One Member Limited Liability Company 1 in accordance with Decision No. 045/QĐ-TCTD of the Chairman of the Board of Directors of Vietnam Pharmaceutical Corporation. Pursuant to Decision No. 2290/QĐ-BYT dated 12 June 2015 of the Minister of Health approving the equitization plan, the Company was transformed to a joint stock company under the name Central Pharmaceutical CPC1.JSC.

The Company was approved to become a public company under Official Dispatch No. 3339/UBCK-GSĐC dated 29 May 2017 of the State Securities Commission. The Company's shares have been officially listed on the UPCoM since from 12 June 2018 under the stock code DP1.

The Company operates under the Business Registration Certificate No. 0100108536 issued by Hanoi Department of Planning and Investment on 4 January 2016. The Company also received subsequent amended Business Registration Certificates with the latest is the 16th amendment being granted on 6 May 2022.

The principal activities during the year of the Company are wholesale and retail of medicines, medical equipment, cosmetics and hygiene products.

The Company's normal course of business cycle is 12 months.

The Company's head office is located at No. 87 Nguyen Van Troi Street, Phuong Liet Ward, Hanoi, Vietnam.

Company structure

In 2025, the Company has 1 wholesale facility and 4 dependent accounting branches ("subsidiaries"). Details are as follows:

<u>Name</u>	<u>Location</u>
Central Pharmaceutical CPC1.JSC - Wholesale facility No. 1	Counter 438, 4th floor, Hapulico Pharmaceutical and Equipment Center, 24T1 building, No.1 Nguyen Huy Tuong street, Thanh Xuan Ward, Hanoi
Central Pharmaceutical CPC1.JSC - Ho Chi Minh City Branch	No. 297/24A, Ly Thuong Kiet Street, Phu Tho Ward, Ho Chi Minh City
Central Pharmaceutical CPC1.JSC - Quang Ninh Branch	No. 146, Alley 3, Cao Thang Street, Ha Lam Ward, Quang Ninh Province

Central Pharmaceutical
CPC1.JSC - Da Nang Branch

Lot 75-76-77, Residential Area No. 2, Phan Lang Street,
Thanh Khe Ward, Da Nang City

Central Pharmaceutical
CPC1.JSC - Nghe An Branch

No. 11, Lenin Street, Block 19, Vinh Phu Ward, Nghe
An Province

2. BASIS OF PREPARATION

2.1 *Applicable Accounting Standards and Regimes*

The financial statements of the Company, which are expressed in Vietnam dong ("VND"), are prepared in accordance with Vietnamese Enterprise Accounting System and Vietnamese Accounting Standards issued by the Ministry of Finance as per:

- ▶ Decision No. 149/2001/QĐ-BTC dated 31 December 2001 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 1);
- ▶ Decision No. 165/2002/QĐ-BTC dated 31 December 2002 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 2);
- ▶ Decision No. 234/2003/QĐ-BTC dated 30 December 2003 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 3);
- ▶ Decision No. 12/2005/QĐ-BTC dated 15 February 2005 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 4); and
- ▶ Decision No. 100/2005/QĐ-BTC dated 28 December 2005 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 5).

Accordingly, the accompanying financial statements, including their tilization are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the financial position and results of operations and cash flows of the Company in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

2.2 *Applied accounting documentation system*

The Company's applied accounting documentation system is the computer based system.

2.3 *Fiscal year*

The Company's fiscal year applicable for the preparation of its financial statements starts on 1 January and ends on 31 December.

2.4 *Accounting currency*

The financial statements are prepared in VND which is also the Company's accounting currency.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Cash

Cash comprises cash on hand and cash at banks.

3.2 Inventories

Inventories are measured at the lower of historical costs and net realisable value. The cost of inventories comprise costs of purchase and other directly related cost incurred in bringing the inventories to their present location and condition. If the net realizable value is lower than historical costs, it must be calculated according to the net realizable value.

Net realisable value ("NRV") represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

The Company applies the perpetual inventory method to account for ending inventory of goods with purchase costs determined by the weighted average method.

Provision for obsolete inventories

An inventory provision is created for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, and other inventories owned by the Company, based on appropriate evidence of impairment available at the balance sheet date..

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the income statement. When inventories are expired, obsolete, damaged or become useless, the difference between the provision previously made and the historical cost of inventories are included in the income statement.

3.3 Receivables

Receivables are presented in the financial statements at the carrying amounts due from customers and other debtors, after provision for doubtful debts.

The provision for doubtful debts represents amounts of outstanding receivables at the balance sheet date which are doubtful of being recovered. Increases or decreases to the provision balance are recorded as general and administrative expenses in the income statement. When bad debts are determined as unrecoverable and accountant writes off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the income statement.

3.4 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use and the costs of dismantling and removing the asset and restoring the site on which it is located, if any. Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the income statement.

3.5 *Leased assets*

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset and the arrangement conveys a right to use the asset.

Where the Company is the lessee

Rentals under operating leases are charged to the income statement on a straight-line basis over the lease term.

Where the Company is the lessor

Assets under operating leases are recorded as fixed assets on the balance sheet.

Income from operating leases is recognised in the income statement on a straight-line basis over the lease term.

3.6 *Intangible fixed assets*

Intangible assets are stated at cost less accumulated amortisation.

The cost of an intangible asset comprises its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use.

Expenditures for additions, improvements are added to the carrying amount of the assets and other expenditures are charged to the income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the income statement.

Land use rights

Land use rights include long-term land use rights.

3.7 *Depreciation and amortisation*

Depreciation of tangible fixed assets and amortisation of intangible assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structure	5 – 25 years
Machinery and equipment	3 – 10 years
Transportation vehicles	5 – 10 years
Office equipment	3 – 7 years
Copyright, computer software	5 years

Long-term land use rights without amortisation.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

3.8 *Borrowing costs*

Borrowing costs consist of interest and other costs that the Company incurs in connection with the borrowing of funds. Borrowing costs are recorded as expense during the year in which they are incurred.

3.9 *Construction in progress costs*

Construction in progress represents the cost of purchasing new assets that have not been installed or the cost of construction that has not been completed. Construction in progress is recorded at cost, including all costs necessary to build new or repair, renovate, expand or re-equip the technical works such as construction costs, equipment costs, project management costs, construction investment consulting costs and borrowing costs eligible for capitalization.

Construction in progress is transferred to the appropriate fixed asset account when the assets are installed or the construction project is completed and depreciation of the assets begins when the assets are ready for their intended use. Construction in progress is recognised as an expense in the year in which it does not qualify for recognition as a fixed asset.

3.10 *Prepaid expenses*

Prepaid expenses are reported as short-term or long-term prepaid expenses in the balance sheet and amortised over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses. Includes the following costs:

- ▶ Software license costs;
- ▶ Insurance costs;
- ▶ Office rent, land rent paid in advance (*);
- ▶ Tools and supplies dispatched; and
- ▶ Fixed asset repair costs.

() Prepaid land rental*

Prepaid land rental includes the unamortised balance of advance payment under the land lease contract signed with Tan Tao Investment and Industry Joint Stock Company on 21 October 2005 and 21 February 2017 with lease terms from 21 October 2005 to 21 October 2050 and from 21 February 2017 to 16 August 2050. According to Circular 45/2013/TT-BTC issued by the Ministry of Finance on 25 April 2013, the above prepaid land rental is recorded as long-term prepaid expense and is allocated to long-term prepaid expenses over the remaining term of the lease contract.

3.11 *Investments*

Investment in other entities

Investment in other entities are recorded at cost. Investments in other entities include investments in equity instruments but the enterprise does not have control, joint control or significant influence over the investee.

Provision for diminution in value of investments



3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Provision of the investment is made when there are reliable evidences of the diminution in value of those investments at the balance sheet date. Increases or decreases to the provision balance are recorded as finance expense in the income statement

3.12 *Payables and accruals*

Payables and accruals are recognised for amounts to be paid in the future for goods and services received, whether or not billed to the Company.

3.13 *Foreign currency transactions*

Transactions in currencies other than the Company's reporting currency (VND) are recorded at the actual exchange rates at transaction dates, determined as follows:

- ▶ Transactions resulting in receivables are recorded at the buying exchange rate of the commercial banks designated for collection;
- ▶ Transactions resulting in liabilities are recorded at the selling exchange rate of commercial banks designated for payment of the transactions; and
- ▶ Payments for assets or expenses without liabilities initially being recognised are recorded at the buying exchange rate of the commercial banks that processed these payments.

At the end of the year, monetary balances denominated in foreign currencies are translated at the actual transaction exchange rates at the balance sheet date, determined as follows:

- ▶ Monetary assets are translated at buying exchange rate of the commercial bank where the Company conducts transactions regularly; and
- ▶ Monetary liabilities are translated at selling exchange rate of the commercial bank where the Company conducts transactions regularly.

All foreign exchange differences incurred are recorded in the income statement.

3.14 *Equity*

Common shares

Common shares are recorded at issue price less costs directly attributable to the issuance of the shares, after deducting tax effects.

3.15 *Appropriation of net profits*

Net profit after tax is available for appropriation to shareholders after approval in the annual general meeting, and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnam's regulatory requirements.

The Company maintains the following reserve funds which are appropriated from the Company's net profit as proposed by the Board of Directors and subject to approval by shareholders at the Annual General Meeting of Shareholders.

Investment and development fund

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

This fund is set aside for use in the Company's expansion of its operation or of in-depth investment

Bonus and welfare fund

This fund is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits, and presented as a liability on the balance sheet

3.16 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognised

Sale of goods

Revenue is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

Rendering of services

Revenue is recognized when services are completed and accepted by customers.

Rental income

Rental income from assets leased under operating leases is recognised in the income statement on a straight-line basis over the lease term.

Dividend and profit distribution income

Dividend and profit distribution income are recognized when Company is entitled to receive dividends or when the Company are entitled to receive profits from its capital contributions.

Interest income

Interest is recognized on an accrual basis based on the time and actual interest rate for each period.

3.17 Taxation

Current income tax

Current tax assets and liabilities for the current and prior years are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted at the balance sheet date.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Current income tax is charged or credited to the income statement, except when it relates to items recognised directly to equity, in which case the current income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Company to set off current tax assets against current tax liabilities and when the Company intends to settle its current tax assets and liabilities on a net basis.

Deferred tax is provided using the liability method on temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- ▶ Where the deferred tax liability arises from the initial recognition of an asset or liability in a transaction which at the time of the related transaction affects neither the accounting profit nor taxable profit or loss;
- ▶ In respect of taxable temporarily differences associated with investments in subsidiaries and associates, and interests in joint ventures where timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profit will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilised, except:

- ▶ Where the deferred tax asset in respect of deductible temporary difference which arises from the initial recognition of an asset or liability which at the time of the related transaction, affects neither the accounting profit nor taxable profit or loss;
- ▶ In respect of deductible temporarily differences associated with investments in associates, and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Previously unrecognised deferred tax assets are re-assessed at each balance sheet date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be utilised.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the end of the reporting period.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

3.17 *Taxation (continued)*

Deferred tax (continued)

Deferred tax is charged or credited to the income statement, except when it relates to items recognised directly to equity, in which case the deferred tax is also dealt with in the equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Company to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority:

- ▶ Either the same taxable entity; or
- ▶ When the Company intends either to settle current tax liabilities and assets on a net basis or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

3.18 *Earnings per share*

Basic earnings per share amounts are calculated by dividing net profit/(loss) after tax for the year attributable to ordinary shareholders of the Company (after adjusting for the bonus and welfare fund) by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing the net profit after tax attributable to ordinary equity holders of the Company (after adjusting for interest on the convertible preference shares) by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

3.19 *Segment reporting*

The Company's principal business activities are wholesale and retail of medicines, medical equipment, cosmetics and hygiene products. In addition, these activities are taking place within Vietnam. Therefore, the Company's risks and profitability are not significantly affected by differences in the products that the Company trades or by the Company's operations in different geographical areas. Therefore, the Company's management considers that the Company has only one segment according to business activities and geographical areas and the Company does not present segment report by business sector and segment report by geographical areas.

3.20 *Related parties*

xParties are considered to be related parties of the Company if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Company and other party are under common control or under common significant influence. Related parties can be enterprise or individual, including close members of their families.

4. CASH

	30 Jun 2025	<i>Unit: VND</i> 01 Jan 2025
Cash on hand	1,015,300,166	216,787,578
Cash at banks	56,946,021,046	9,290,749,159
Cash in transit		
Total	57,961,321,212	9,507,536,737

5. SHORT-TERM TRADE RECEIVABLES AND ADVANCES TO SUPPLIERS

5.1 Short-term trade receivables

	30 Jun 2025	<i>Unit: VND</i> 01 Jan 2025
Bach Mai Hospital	13,870,084,000	22,405,230,000
Cho Ray Hospital	26,666,117,500	17,636,010,700
Kien Giang General Hospital	8,016,405,600	5,617,795,700
Hue Central Hospital	10,476,485,900	4,307,264,100
Thai Nguyen Central Hospital	9,115,713,700	5,535,189,900
Military Hospital 175	19,457,585,660	19,841,211,150
Da Nang Hospital	8,731,199,120	3,038,196,100
Center for Medical Review and Tertiary Care payment	17,282,898,054	15,486,710,254
Other customers	446,622,247,079	392,502,857,063
Receivables from related parties	-	-
Total	560,238,736,613	486,370,464,967

Provision for doubtful short-term receivables (2,898,358,898) (3,170,157,489)

Details of movements of provision for doubtful short-term receivables:

	Current period	Previous period
Beginning balance	3,170,157,489	2,854,962,216
Add: Provision made during the year	861,754,729	4,147,170,204
Less: Reversal of provision during the year	(1,133,553,320)	(2,656,304,357)
Ending balance	2,898,358,898	4,345,828,063

5.2 Short-term advances to suppliers

	30 Jun 2025	<i>Unit: VND</i> 01 Jan 2025
ASYNMED PTE. LTD	4,009,151,614	32,675,604
Bliss Pharma Distribution and Consultancy Corp.	5,806,231,129	245,870,989
Nhat Anh Pharmaceutical Company Ltd	7,913,500,000	5,890,000,000
REIWA HEALTHCARE INC.	3,654,216,592	-
Others	4,464,455,056	5,206,035,556
Total	25,847,554,391	11,374,582,149

6. OTHER SHORT-TERM RECEIVABLES

Items	30 Jun 2025		01 Jan 2025	
	Amount	Provision	Amount	Provision
Other receivables	337,888,073		661,993,076	
Advances receivables	718,000,000			
Receivables for entrusted import services (*)			1,714,502,720	
Total	1,055,888,073	-	2,376,495,796	-

(*) These are receivables from entrusted import service related to the value of imported shipments, import tax, and consignment value added tax that have been completed during the year but have not been refunded by the trustors.

7. DOUBTFUL DEBTS

Debtor	30 Jun 2025		01 Jan 2025	
	Cost	Recoverable amount	Cost	Recoverable amount
30-04 Hospital	1,214,365,229	151,195,485	1,180,366,679	354,110,004
Yen Thuy Medical Center	531,708,500	265,854,250	531,708,500	265,854,250
Other overdue receivables	4,500,211,043	2,930,876,139	5,737,278,820	3,659,232,256
Total	6,245,284,772	3,347,925,874	7,449,353,999	4,279,196,510

8. INVENTORIES

Items	30 Jun 2025		01 Jan 2025	
	Cost	Provision	Cost	Provision
Goods in transit	74,133,881,271		82,266,113,455	
Merchandise	651,175,827,095	(23,079,064,087)	657,579,451,107	(24,005,875,574)
Total	725,309,708,366	(23,079,064,087)	739,845,564,562	(24,005,875,574)

Detail of movements of provision for obsolete inventories:

	Current period	Previous period
Beginning balance	24,005,875,574	43,158,812,699
Add: Provision made during the year	-	6,465,276,588
Less: Reversal of provision during the year	926,811,487	(683,918,849)
Ending balance	23,079,064,087	48,940,170,438

9. TANGIBLE FIXED ASSETS

Unit: VND

Items	Buildings and structures	Machinery and equipment	Vehicles, Transportation equipment	Management equipment, tools, others	Total
Cost					
Beginning balance	<u>151,944,878,712</u>	<u>35,497,848,095</u>	<u>23,059,174,829</u>	<u>3,813,244,117</u>	<u>214,315,145,753</u>
- Purchase in the period	-	-	-	-	-
- Finished construction investment					-
- Other increase					-
- Transition to investment real estate					-
- Liquidation, sale	-	-	-	-	-
- Other decrease					
Ending balance	<u>151,944,878,712</u>	<u>35,497,848,095</u>	<u>23,059,174,829</u>	<u>3,813,244,117</u>	<u>214,315,145,753</u>
Accumulated depreciation					
Beginning balance	<u>102,042,249,790</u>	<u>33,593,552,124</u>	<u>15,079,524,049</u>	<u>3,078,653,203</u>	<u>153,793,979,166</u>
- Depreciation for the year	1,758,481,641	1,054,116,937	504,855,944	295,532,160	3,612,986,682
- Other increase					-
- Transition to investment real estate					
- Liquidation, sale	-	-	-	-	-
- Other decrease					
Ending balance	<u>103,800,731,431</u>	<u>34,647,669,061</u>	<u>15,584,379,993</u>	<u>3,374,185,363</u>	<u>157,406,965,848</u>
Net carrying amount					
- Beginning of year	49,902,628,922	1,904,295,971	7,979,650,780	734,590,914	60,521,166,587
- Ending of year	48,144,147,281	850,179,034	7,474,794,836	439,058,754	56,908,179,905

10. INTANGIBLE FIXED ASSETS

Unit: VND

Items	Land use rights	Others	Total
Cost			
Beginning balance	<u>27,870,452,800</u>	<u>2,701,213,200</u>	<u>30,571,666,000</u>
- Purchase in the period	-	-	-
- Other increase			-
- Liquidation, sale			-
- Other decrease			-
Ending balance	<u>27,870,452,800</u>	<u>2,701,213,200</u>	<u>30,571,666,000</u>
Accumulated amortisation			-
Beginning balance	<u>5,220,000</u>	<u>2,701,213,200</u>	<u>2,706,433,200</u>
- Amortisation for the year	-	-	-
- Other increase			-
- Liquidation, sale			-
- Other decrease			-
Ending balance	<u>5,220,000</u>	<u>2,701,213,200</u>	<u>2,706,433,200</u>
Net carrying amount			-
- Beginning of year	27,865,232,800	-	27,865,232,800
- Ending of year	27,865,232,800	-	27,865,232,800

11. LONG-TERM INVESTMENTS

Unit: VND

	30 Jun 2025					01 Jan 2025				
	Capital contribution ratio	Number of shares	Cost	Provision	Fair value	Capital contribution ratio	Number of shares	Cost	Provision	Fair value
CPC1 Pharmaceutical Joint Stock Company – Hanoi (i)	16.43%	2,666,666	27,776,985,675	-	214,879,946,280	16.43%	2,666,666	27,776,985,675	-	365,333,242,000
Mekophar Chemical Pharmaceutical Joint Stock Company (i)	0.26%	67,082	2,790,867,722	(813,949,394)	1,976,918,328	0.26%	67,082	2,790,867,722	(879,030,722)	1,911,837,000
Ha Tinh Pharmaceutical Joint Stock Company (i)	1.00%	99,825	971,029,662	-	2,445,712,500	1.00%	99,825	971,029,662	-	1,996,500,000
TV. Pharm Pharmaceutical Joint Stock Company (i)	0.10%	46,816	300,659,375	(36,659,375)	264,000,000	0.10%	46,816	300,659,375	-	(ii)
Vidipha Central Pharmaceutical Joint Stock Company	0.10%	21,600	472,871,724	-	663,660,000	0.10%	21,600	472,871,724	-	779,200,000
Tuyen Quang Pharmaceutical Joint Stock Company	0.40%	18,000	197,784,303	-	(ii)	0.40%	18,000	197,784,303	-	(ii)
Sanofi-Synthelabo Vietnam Pharmaceutical Joint Stock Company	0.00%	10	1,000,000	-	(ii)	0.00%	10	1,000,000	-	(ii)
Total			32,511,198,461	(850,608,769)				32,511,198,461	(879,030,722)	

- (i) The fair value of investments in shares of these companies is determined by the closing price of shares on the stock exchanges at the end of the accounting period of the year.
- (ii) The Company has not yet collected the necessary information to assess the fair value of the investment value in these companies because the shares of these companies are not listed on the stock exchange.

12. PREPAID EXPENSES

Items	Unit: VND	
	30 Jun 2025	01 Jan 2025
Short-term		
- Dispatched tools and supplies;	1,066,244,373	1,840,213,756
Total	1,066,244,373	1,840,213,756
Long-term		
- Prepaid land rental (i)	24,653,170,252	24,933,986,855
Total	24,653,170,252	24,933,986,855

13. TRADE PAYABLES AND SHORT-TERM ADVANCES FROM CUSTOMERS

13.1 Short-term trade payables

Items	30 Jun 2025		01/01/2025	
	Amount	Payable amount	Amount	Payable amount
Angeion Medical International Pte. Ltd.	26,075,507,408	26,075,507,408	16,581,663,447	16,581,663,447
Minh Y Pharmaceutical Company Limited	21,925,617,736	21,925,617,736	16,341,763,645	16,341,763,645
Celltrion, INC.	25,439,258,860	25,439,258,860		
Ever Neuro Pharma GMBH	40,524,962,793	40,524,962,793	46,538,293,475	46,538,293,475
Hyphens Pharma Pte. Ltd	45,889,753,426	45,889,753,426	142,810,055,819	142,810,055,819
Inbiotech L.t.d	17,875,382,388	17,875,382,388	5,600,000,096	5,600,000,096
Panpharma GmbH	31,879,270,280	31,879,270,280	8,051,242,968	8,051,242,968
RV Group (S) PTE. LTD	21,105,224,000	21,105,224,000	15,683,203,800	15,683,203,800
Other suppliers	207,986,677,731	207,986,677,731	191,290,410,007	191,290,410,007
Payables to related parties	8,600,778,223	8,600,778,223	6,006,023,810	6,006,023,810
Total	447,302,432,845	447,302,432,845	448,902,657,067	448,902,657,067

13.2 Short-term advances from customers

	Unit: VND	
	30 Jun 2025	01 Jan 2025
Project Management Board Technical Support for Global Fund to Fight HIV, AIDS	2,000,000,000	
Phi Long MEP JSC	1,437,577,258	3,274,273,857
Others	3,128,026,383	1,753,223,111
Total	6,565,603,641	5,027,396,968

14. TAXES AND RECEIVABLES, PAYABLES TO THE STATE

Unit: VND

Items	01 Jan 2025	Payable during the period	Paid during the period	30 Jun 2025
Payables				
- Value added tax	88,413,284	87,589,237,582	87,309,286,487	368,364,379
- Special consumption tax				
- Import & Export duties		989,372,145	989,372,145	
- Corporate income tax	30,544,669,828	14,812,271,039	13,000,000,000	32,356,940,867
- Personal income tax				
- National resource tax				
- Land tax and land rent		5,621,720,847	5,621,720,847	
- Other taxes		7,000,000	7,000,000	
- Fees, charges and others	16,896,282,797	308,904,923	308,904,923	16,896,282,797
Total	47,529,365,909	109,328,506,536	107,236,284,402	49,621,588,043
Receivables				
- Value added tax	18,898,395,710	80,306,592,580	83,312,288,757	15,892,699,533
- Value added tax debit	138,528,103		138,528,103	
- Special consumption tax				
- Import & Export duties				
- Corporate income tax				
- Personal income tax	90,506,868	1,538,629,447	968,419,065	660,717,250
- National resource tax				
- Land tax and land rent				
- Other taxes				
Total	19,127,430,681	81,845,222,027	84,419,235,925	16,553,416,783

15. SHORT-TERM ACCRUED EXPENSES

Items	30 Jun 2025	Unit: VND 01 Jan 2025
- Interest expense	249,203,293	
- Accruals	7,613,945,337	5,446,809,923
- Others	320,154,455	
Total	8,183,303,085	5,446,809,923

16. OTHER SHORT-TERM PAYABLES

Items	30 Jun 2025	Unit: VND 01 Jan 2025
- Surplus of assets awaiting resolution		
- Trade union fees	39,116,800	38,097,840
- Short-term deposits, collateral (imported goods)	-	
- Short-term deposits, collateral (domestic)	-	
- Dividends and profits payable		
- Other payables	26,786,150,152	13,631,882,370
- Other receivables credit		
- Amounts paid and collected on behalf of trustor (*)	315,000	5,202,384,677
Total	26,825,581,952	18,872,364,887

(*) These are payables related to entrusted import operations.

17. SHORT-TERM LOANS

Unit: VND

	30 Jun 2025		Movement during the year		01 Jan 2025	
	Amount	Payable	Increase	Decrease	Amount	Payable
Loans from banks	404,527,187,252	404,527,187,252	574,568,505,095	495,344,197,299	325,302,879,456	325,302,879,456
Loans from individuals	11,291,000,000	11,291,000,000	3,385,000,000	3,035,000,000	10,941,000,000	10,941,000,000
Total	415,818,187,252	415,818,187,252	577,953,505,095	498,379,197,299	336,243,879,456	336,243,879,456

17.1. Short-term loans from individuals

Details of short-term loans from individuals are as follows:

Individual	30 Jun 2025	Principal and interest payment term	Annual interest	Security method
Loans from individuals	11,291,000,000	Principal payable on demand. Interest payable quarterly.	5%	Unsecured loan
Total	11,291,000,000			

18. OWNERS' EQUITY

18.1 Increase and decrease in owners' equity

Unit: VND

For the period ended 30 June 2024

	Issued share capital	Investment development fund	Undistributed earnings	Total
Balance as of 1 Jan 2024	209,790,000,000	2,444,991,780	139,259,609,169	351,494,600,949
Net profit for the period			58,176,615,421	58,176,615,421
2023 dividends			(31,468,500,000)	(31,468,500,000)
2023 appropriation to bonus fund for Board of Directors ("BoD"), Supervisory Board (SB), Board of Management		-	(392,000,000)	(392,000,000)
2023 appropriation to bonus and welfare funds		-	(14,260,816,826)	(14,260,816,826)
Others				
As of 30 Jun 2024	209,790,000,000	2,444,991,780	151,314,907,764	363,549,899,544

For the period ended 31 June 2025

	Issued share capital	Investment development fund	Undistributed earnings	Total
Balance as of 1 Jan 2025	209,790,000,000	2,444,991,780	299,295,143,281	511,530,135,061
Net profit for the period			53,620,487,785	53,620,487,785
2024 dividends (*)			(25,174,800,000)	(25,174,800,000)
2024 appropriation to bonus fund for BoD, Board of Management, Chief Accountant, Governance Officer cum Secretary (*)		-	(347,583,333)	(347,583,333)
2024 appropriation to bonus and welfare funds (*)		-	(2,000,000,000)	(2,000,000,000)
Bonus for completing the plan and exceeding the 2024 profit target (**)		-	(7,418,390,485)	(7,418,390,485)
Others				
As of 30 Jun 2025	209,790,000,000	2,444,991,780	317,974,857,248	530,209,849,028

(*) The Company distributed dividends and set aside bonus and welfare funds from 2023 profits in accordance with Resolution No. 23/NQDHCD dated 17 April 2025 of the Company's General Meeting of Shareholders.

(**) The Company has allocated a bonus fund for completing the plan and exceeding the 2024 profit plan target according to Resolution No. 23/NQDHCD dated 17 April 2025 of the Company's General Meeting of Shareholders.

18. OWNERS' EQUITY (continued)

18.2 Details of owners' capital

	30 Jun 2025			01 Jan 2025		
	Total	Common shares	Ownership (%)	Total	Common shares	Ownership (%)
Vietnam Pharmaceutical Corporation	13,721,550	13,721,550	65.41%	13,721,550	13,721,550	65.41%
Mr. Le Nam Thang	1,689,000	1,689,000	8.05%	1,689,000	1,689,000	8.05%
Ms. Le Thi Kim Anh	1,518,800	1,518,800	7.24%	1,518,800	1,518,800	7.24%
Mr. Nguyen Doan Liem	1,210,940	1,210,940	5.77%	1,210,940	1,210,940	5.77%
Others	2,838,710	2,838,710	13.53%	2,838,710	2,838,710	13.53%
Total	20,979,000	20,979,000	100.00%	20,979,000	20,979,000	100.00%

Par value of outstanding share: VND 10,000/share.

18.3 Capital transactions with owners and distribution of dividends, profits

	Unit: VND	
	Current year	Previous year
Contributed capital		
Beginning balance	209,790,000,000	209,790,000,000
Ending balance	209,790,000,000	209,790,000,000

18.4 Dividends

	Unit: VND	
	Current year	Previous year
Dividends declared during the year		
2024 Dividends	25,174,800,000	
2023 Dividends		31,468,500,000
Total	25,174,800,000	31,468,500,000

18. OWNERS' EQUITY (continued)

18.5 Shares

	Ending balance		Beginning balance	
	Quantity	Amount	Quantity	Amount
	(Share)	(VND)	(Share)	(VND)
Approved shares	20,979,000	209,790,000,000	20,979,000	209,790,000,000
Issued shares	20,979,000	209,790,000,000	20,979,000	209,790,000,000
Common shares	20,979,000	209,790,000,000	20,979,000	209,790,000,000
Preferred shares	-	-	-	-
Number of shares outstanding	20,979,000	209,790,000,000	20,979,000	209,790,000,000
Common shares	20,979,000	209,790,000,000	20,979,000	209,790,000,000
Preferred shares	-	-	-	-

19. OFF-BALANCE SHEET ITEMS

	Unit: VND	
	Ending balance	Beginning balance
Imported goods entrusted by third party		20,606,125,993
Foreign currencies		
- USD	11,839	11,856
- EUR	268	279

20. REVENUES

20.1 Revenue from goods sold and services rendered

	Unit: VND	
	Current year	Previous year
Total revenue	1,032,688,200,351	1,019,095,566,294
In which:		
- Sale of goods	1,024,810,542,436	1,011,126,211,569
- Rendering of services	7,877,657,915	7,969,354,725
Revenue deductions		
- Sales returns		
Net revenue	1,032,688,200,351	1,019,095,566,294
In which:		
Revenue from other parties	1,031,379,283,094	1,017,735,620,565
Revenue from related parties	1,308,917,257	1,359,945,729

20. REVENUES (continued)

20.2 Finance income

	<i>Unit: VND</i>	
	Current year	Previous year
Interest income	10,845,821	10,925,709
Dividends, profit earned	241,445,786	198,367,000
Others	33,144,164	103,532,591
Realized foreign exchange gains	11,269,645,370	6,076,807,425
Total	11,555,081,141	6,389,632,725

21. COST OF GOODS SOLD AND SERVICES RENDERED

	<i>Unit: VND</i>	
	Current year	Previous year
Cost of goods sold and services rendered	874,719,333,815	839,859,222,007
Reversal of provision/provision for obsolete inventories	(926,811,487)	6,465,276,588
Total	873,792,522,328	846,324,498,595

22. FINANCE EXPENSES

	<i>Unit: VND</i>	
	Current year	Previous year
Interest expenses	8,401,478,788	6,134,671,848
Realized foreign exchange losses	14,354,823,129	12,426,422,201
Unrealized foreign exchange losses	4,632,038,857	61,581,246
Reversal of provision/provision for devaluation of investments	(28,421,953)	(335,410,000)
Total	27,359,918,821	18,287,265,295

23. SELLING EXPENSES AND ADMINISTRATIVE EXPENSES

	<i>Unit: VND</i>	
	Current year	Previous year
Selling expenses incurred during the year		
Labour costs	27,491,870,372	31,504,519,882
Material costs	2,184,180,411	3,309,756,116
Tools and supplies costs	1,125,506,835	636,641,818
Depreciation and amortisation	3,612,986,682	3,382,058,724
Expenses for external services	11,238,073,315	14,159,043,229
Others	14,585,020,547	10,825,620,241
Total	60,237,638,162	63,817,640,010

23. SELLING EXPENSES AND ADMINISTRATIVE EXPENSES (continued)

Administrative expenses incurred during the year

Management staff costs	7,812,134,716	5,959,079,890
Material costs		
Office supplies cost	1,217,113,778	327,464,090
Depreciation and amortisation		6,744,999
Taxes, fees and charges	6,145,343,983	
Provision	(271,798,591)	1,490,865,847
Expenses for external services	164,998,902	2,904,852,424
Other cash expenses	3,711,441,101	10,846,948,843
Land rental		2,852,069,347
Total	18,779,233,889	24,388,025,440

24. OTHER INCOME AND EXPENSES

	Current year	Previous year
Other income	3,283,232,338	95,956,435
Compensation	3,283,232,338	
Others		95,956,435
Other expenses	309,241,806	40,192,435
Penalty	309,241,806	25,267,435
Others		14,925,000
NET OTHER PROFIT (LOSS)	2,973,990,532	55,764,000

25. PRODUCTION AND OPERATING COSTS

	Current year	Previous year
Cost of purchasing goods for sale	874,719,333,815	839,859,222,007
Material costs	2,184,180,411	3,309,756,116
Labour costs	35,304,005,088	37,463,599,772
Expenses for external services	11,403,072,217	17,063,895,653
Depreciation, amortisation and allocation of land use costs	3,612,986,682	3,388,803,723
Provision/reversal of provision	(271,798,591)	1,490,865,847
Tools and supplies	2,342,620,613	964,105,908
Others	24,441,805,631	24,524,638,431
Total	953,736,205,866	928,064,887,457

26. CORPORATE INCOME TAX

The statutory corporate income tax ("CIT") applicable to the Company is 20% of taxable income.

The Company's tax reports are subject to examination by the tax authorities. Since the application of tax laws and regulations to different types of transactions is susceptible to varying interpretations, the tax amounts presented in the interim financial statements may change upon final determination by the tax authorities.

26.1 CIT expenses

	Unit: VND	
	Current year	Previous year
Current CIT expenses	14,812,271,039	15,839,973,576
Adjustment to previous year's tax expenses		
Deferred tax expense/(income)	(1,384,800,000)	(1,293,055,318)
Total	13,427,471,039	14,546,918,258

The reconciliation between CIT expenses and the accounting profit multiplied by CIT rate is presented below::

	Unit: VND	
	Current year	Previous year
Accounting profit before tax	67,047,958,824	72,723,533,679
CIT expenses at CIT rate of 20%	13,409,591,765	14,544,706,736
<i>Adjustments to increase</i>		
Other non-deductible expenses	7,254,842,153	41,884,922
<i>Adjustments to decrease</i>		
Income from dividends	241,445,786	39,673,400
Others		
CIT expenses	14,812,271,038	14,546,918,258

26.2 Current corporate income tax

Current corporate income tax payable is based on taxable profit for the current period. The Company's taxable profit differs from profit as reported in the interim income statement because it excludes items of income or expense that are taxable or deductible in other periods and it excludes items that are not taxable or deductible for tax purposes. The Company's current corporate income tax payable is calculated using tax rates that have been enacted by the end of the interim reporting period.

26. CORPORATE INCOME TAX (continued)

26.3 Deferred tax assets

The Company has recognised deferred tax assets with movements during the current period and previous period as below:

	Unit: VND	
	Current year	Previous year
Provision for sub-standard goods	4,615,812,818	5,172,221,271
Expenses (legal advice, bonus fund)	1,384,800,000	
Total	6,000,612,818	5,172,221,271

27. TRANSACTIONS WITH REPLATED PARTIES

The list of related parties with controlling relationships and other related parties with material transactions with the Company during the year and as at 30 June 2025 is as follows:

Related parties	Relationship
Vietnam Pharmaceutical Corporation	Parent company
Codupha Central Pharmaceutical Joint Stock Company	Subsidiary of Parent company
Central Phamaceutical Joint Stock Company No.3	Subsidiary of Parent company
Vietnam Medical Products Import - Export Joint Stock Company	Affiliate of Parent company
Danapha Pharmaceutical Joint Stock Company	Affiliate of Parent company
Imexpharm Corporation	Affiliate of Parent company
Hanoi CPC1 Pharmaceutical Joint Stock Company	Entity with a mutual member of Board of Directors ("BoD")
OPC Pharmaceutical Joint Stock Company	Entity with a mutual member of Board of Directors ("BoD")

The list of individuals who are members of the Board of Directors, Board of Management, Board of Supervisors, Audit Committee during the year and at the date of this report is presented in the General Information section.

28. COMMITMENTS

Operating lease commitment

The Company lease lands under operating lease arrangements. The future minimum lease commitments as at the end date of the interim reporting period under these operating lease agreements are as follows:

	Unit: VND	
	Current year	Previous year
1 year or less	8,900,730,570	5,489,762,524
From 1 to 5 years	43,790,860,660	26,736,020,430
More than 5 years	110,250,846,442	73,629,125,885
Total	162,942,437,672	105,854,908,839

29. EARNINGS PER SHARE

The following reflects the income and share data used in the earnings per share computations:

	<i>Unit: VND</i>	
	Current year	Previous year
Profit after tax	53,620,487,785	58,176,615,421
Appropriation to bonus and welfare fund	-	(4,908,830,771)
Net profit after tax attributable to common shareholders	53,620,487,785	53,267,784,650
Weighted average number of common shares for basic earnings per share	20,979,000	20,979,000
Basic earnings per share		
- Basic earnings per share	2,575	2,539
- Dilluted earnings per share	2,575	2,539

There were no common share transactions or potential common share transactions between the end of the interim reporting period and the date of completion of the interim financial statements.

Hanoi, 18 July 2025

Preparer
Truong Thi Hue

Financial Director
Tran Anh Tuan

Acting General Director
Ta Van Dung

